Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis

This study has been completed.
Information provided by (Responsible Party):
Akorn, Inc. Identifier:
First received: March 21, 2012
Last updated: July 16, 2013
Last verified: May 2012
The purpose of this study is to evaluate the onset and duration of action of two concentrations of AKF-1 Ophthalmic Solution compared to vehicle in the conjunctival allergen challenge (CAC) model of acute allergic conjunctivitis.

Condition Intervention Phase
Allergic Conjunctivitis
Drug: AKF-1
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Akorn, Inc.:

Primary Outcome Measures:
  • Ocular Itching at defined time points up to 2 weeks [ Time Frame: Baseline to day 14 ]
  • Ocular Redness at defined time points up to 2 weeks [ Time Frame: Baseline to day 14 ]

Enrollment: 90
Study Start Date: March 2012
Study Completion Date: April 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AKF-1 0.025% Drug: AKF-1
1 drop AKF-1 0.025% in each eye at 2 separate times during a 14 day period
Experimental: AKF-1 0.035% Drug: AKF-1
1 drop AKF-1 0.035% in each eye at 2 separate times during a 14 day period
Placebo Comparator: AKF-1 0% Drug: AKF-1
1 drop 0% in each eye at 2 separate times during a 14 day period


Ages Eligible for Study:   10 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • positive bilateral conjunctival allergen challenge (CAC) reaction

Exclusion Criteria:

  • known contraindications or sensitivities to the study medication or its components
  • any ocular condition that, in the opinion of the investigator, could affect the subjects safety or trial parameters
  • use of disallowed medication during the period indicated prior to the enrollment or during the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01561521

United States, Massachusetts
Andover Eye Associates
Andover, Massachusetts, United States, 01810
Sponsors and Collaborators
Akorn, Inc.
  More Information

Responsible Party: Akorn, Inc. Identifier: NCT01561521     History of Changes
Other Study ID Numbers: 11-100-0008
Study First Received: March 21, 2012
Last Updated: July 16, 2013

Additional relevant MeSH terms:
Conjunctivitis, Allergic
Conjunctival Diseases
Eye Diseases
Hypersensitivity, Immediate
Immune System Diseases
Ophthalmic Solutions
Pharmaceutical Solutions processed this record on May 25, 2017